Denis Gestin is appointed to Intressa Vascular Board of Directors

Gembloux, Belgium, January 9, 2024 – Intressa Vascular SA, a clinical-stage MedTech company using its proprietary multilayer stent braiding technology to develop an innovative stent for aortic dissection, today announces the appointment of Denis Gestin as independent director.

Former medical device top executive, Denis Gestin, brings more than thirty years of experience in the management and commercial development of medical technologies companies, having held positions as SVP for Abbott and President of the International Division (OUS) at St. Jude Medical. Today active in the Board of Directors of several start-ups, Denis shares Intressa Vascular’s value and dedication to bringing new options to patients with aortic dissection, a life-threatening cardiovascular condition with poor outcome and suboptimal treatment options on an addressable market of more than EUR 2 billion.

“Denis Gestin will be a critical member of the Board of Director at Intressa Vascular, to advance the company’s product development, including clinical studies and regulatory pathways, and prepare market adoption of the multilayer stent in aortic dissection”, says Philippe Felten, Chairman of the Board.

“I believe that Intressa Vascular is well positioned to make a great impact on the treatment of aortic dissection through their unique multilayer stent braiding technology, said Denis Gestin. I am excited to join Intressa Vascular and work with the distinguished and accomplished team of employees, directors and scientific advisors to better support patients facing such life-threatening disease as aortic dissection”, says Denis Gestin, Director of the Board.

“We are very excited to welcome Denis as an independent board member. As we are progressing closer to the market, his expertise and international exposure both as MedTech executive and Director will be highly valuable and will complement our team with high impact”, says Pierre Douette, CEO.